LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

Kodu・Aktsiate loetelu・United Therapeutics Corp

United Therapeutics Corp

Avatud

SektorTervishoid

547.1 -0.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

543.92

Max

550.22

Põhinäitajad
By Trading Economics
Sissetulek	-89M 275M
Müük	-8.7M 782M
P/E Sektori keskmine	20.134 49.888
Aktsiakasum	5.82
Kasumimarginaal	35.176
Töötajad	1,400
EBITDA	-176M 348M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+21.1% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-1.5B 23B
Eelmine avamishind	547.14
Eelmine sulgemishind	547.1

Uudiste sentiment

By Acuity

50%

139 / 344 Pingereas Healthcare

United Therapeutics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuni 2026, 19:20 UTC

Suurimad hinnamuutused turgudel

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7. juuni 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7. juuni 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7. juuni 2026, 18:00 UTC

Tulu

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6. juuni 2026, 12:40 UTC

Omandamised, ülevõtmised, äriostud

Correction to Texas Billionaires Article America's Resort -- WSJ

6. juuni 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. juuni 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. juuni 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. juuni 2026, 00:14 UTC

Omandamised, ülevõtmised, äriostud

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5. juuni 2026, 21:27 UTC

Tulu

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. juuni 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. juuni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. juuni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. juuni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. juuni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. juuni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. juuni 2026, 18:33 UTC

Omandamised, ülevõtmised, äriostud

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. juuni 2026, 17:50 UTC

Tulu

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. juuni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. juuni 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

United Therapeutics Corp Prognoos

Hinnasiht

By TipRanks

21.1% tõus

12 kuu keskmine prognoos

Keskmine 665.9 USD 21.1%

Kõrge 738 USD

Madal 516 USD

Põhineb 10 Wall Streeti analüütiku instrumendi United Therapeutics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi United Therapeutics Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

139 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.